These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 30792720)

  • 1. Current Strategies to Inhibit High Affinity FcεRI-Mediated Signaling for the Treatment of Allergic Disease.
    Gomez G
    Front Immunol; 2019; 10():175. PubMed ID: 30792720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel bispecific DARPin targeting FcγRIIB and FcεRI-bound IgE inhibits allergic responses.
    Zellweger F; Gasser P; Brigger D; Buschor P; Vogel M; Eggel A
    Allergy; 2017 Aug; 72(8):1174-1183. PubMed ID: 27997998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein.
    Eggel A; Buschor P; Baumann MJ; Amstutz P; Stadler BM; Vogel M
    Allergy; 2011 Jul; 66(7):961-8. PubMed ID: 21272035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells.
    Eggel A; Baravalle G; Hobi G; Kim B; Buschor P; Forrer P; Shin JS; Vogel M; Stadler BM; Dahinden CA; Jardetzky TS
    J Allergy Clin Immunol; 2014 Jun; 133(6):1709-19.e8. PubMed ID: 24642143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparable actions of omalizumab on mast cells and basophils.
    Serrano-Candelas E; Martinez-Aranguren R; Valero A; Bartra J; Gastaminza G; Goikoetxea MJ; Martín M; Ferrer M
    Clin Exp Allergy; 2016 Jan; 46(1):92-102. PubMed ID: 26509363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab may not inhibit mast cell and basophil activation in vitro.
    Gericke J; Ohanyan T; Church MK; Maurer M; Metz M
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1832-6. PubMed ID: 25257818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
    Kaplan AP; Giménez-Arnau AM; Saini SS
    Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
    Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
    Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the FcεRI Pathway as a Potential Strategy to Prevent Food-Induced Anaphylaxis.
    Dispenza MC; Bochner BS; MacGlashan DW
    Front Immunol; 2020; 11():614402. PubMed ID: 33391286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance of the Basophil High-Affinity IgE Receptor in Chronic Urticaria: Clinical Experience from a Tertiary Care Institution.
    Deza G; March-Rodríguez A; Sánchez S; Ribas-Llauradó C; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
    J Allergy Clin Immunol Pract; 2019; 7(5):1619-1626.e1. PubMed ID: 30685572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody to FcεRIα Suppresses Immunoglobulin E Binding to High-Affinity Receptor I in Allergic Inflammation.
    Hong JY; Bae JH; Lee KE; Kim M; Kim MH; Kang HJ; Park EH; Yoo KS; Jeong SK; Kim KW; Kim KE; Sohn MH
    Yonsei Med J; 2016 Nov; 57(6):1412-9. PubMed ID: 27593869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-3 but not monomeric IgE regulates FcεRI levels and cell survival in primary human basophils.
    Zellweger F; Buschor P; Hobi G; Brigger D; Dahinden CA; Villiger PM; Eggel A
    Cell Death Dis; 2018 May; 9(5):510. PubMed ID: 29724998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
    MacGlashan D; Saini S; Schroeder JT
    J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of allergy by Fc receptors.
    Bruhns P; Frémont S; Daëron M
    Curr Opin Immunol; 2005 Dec; 17(6):662-9. PubMed ID: 16214316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-IgE treatment in allergic rhinitis.
    Bayar Muluk N; Bafaqeeh SA; Cingi C
    Int J Pediatr Otorhinolaryngol; 2019 Dec; 127():109674. PubMed ID: 31526939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
    Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
    J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaches to target IgE antibodies in allergic diseases.
    Balbino B; Conde E; Marichal T; Starkl P; Reber LL
    Pharmacol Ther; 2018 Nov; 191():50-64. PubMed ID: 29909239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of IgE-mediated allergic reactions by pharmacologically targeting the circadian clock.
    Nakamura Y; Nakano N; Ishimaru K; Ando N; Katoh R; Suzuki-Inoue K; Koyanagki S; Ogawa H; Okumura K; Shibata S; Nakao A
    J Allergy Clin Immunol; 2016 Apr; 137(4):1226-1235. PubMed ID: 26559325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.
    Chang TW; Chen C; Lin CJ; Metz M; Church MK; Maurer M
    J Allergy Clin Immunol; 2015 Feb; 135(2):337-42. PubMed ID: 24948369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FcepsilonRI-alpha siRNA inhibits the antigen-induced activation of mast cells.
    Safaralizadeh R; Soheili ZS; Deezagi A; Pourpak Z; Samiei S; Moin M
    Iran J Allergy Asthma Immunol; 2009 Dec; 8(4):177-83. PubMed ID: 20404387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.